Robin K Avery1, Ravit Arav-Boger, Kieren A Marr, Edward Kraus, Shmuel Shoham, Laura Lees, Brandon Trollinger, Pali Shah, Rich Ambinder, Dionysios Neofytos, Darin Ostrander, Michael Forman, Alexandra Valsamakis. 1. 1 Division of Infectious Diseases, Department of Medicine Johns Hopkins, Baltimore, MD. 2 The Eudowood Division of Pediatric Infectious Diseases, Department of Pediatrics, Johns Hopkins, Baltimore, MD. 3 Division of Nephrology, Department of Medicine, Johns Hopkins, Baltimore, MD. 4 Department of Pharmacy, Johns Hopkins, Baltimore, MD. 5 Division of Pulmonary and Critical Care, Department of Medicine Johns Hopkins, Baltimore, MD. 6 The Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins, Baltimore, MD. 7 Division of Medical Microbiology, Department of Pathology, Johns Hopkins, Baltimore, MD.
Abstract
BACKGROUND: Antiviral-resistant or refractory cytomegalovirus (CMV) infection is challenging, and salvage therapies, foscarnet, and cidofovir, have significant toxicities. Several investigational anti-CMV agents are under development, but more information is needed on outcomes of current treatments to facilitate clinical trial design for new drugs. METHODS: Records of solid organ transplant (SOT) and hematopoietic cell transplant (HCT) recipients at a single center over a 10-year period were reviewed retrospectively to characterize those who had received foscarnet treatment for ganciclovir-resistant or refractory CMV infection. Data were collected on virologic responses, mortality, and nephrotoxicity. RESULTS: Of 39 patients (22 SOT, 17 HCT), 15 had documented ganciclovir resistance mutations and 11 (28%) of 39 had tissue-invasive CMV. Median duration of foscarnet was 32 days. Virologic failure occurred in 13 (33%) of 39 and relapses of viremia occurred in 31%. Mortality was 12 (31%) of 39 and was higher in HCT than SOT (P = 0.001), although ganciclovir resistance was more common in SOT (P = 0.003). Doses of ganciclovir or valganciclovir were low in 10 (26%) of 39 at some time before switching to foscarnet. Renal dysfunction occurred in 20 (51%) of 39 by end of treatment and in 7 (28%) of 25 after 6 months. CONCLUSIONS: Outcomes of existing treatment for ganciclovir-resistant or refractory CMV are suboptimal, in terms of virologic clearance, renal dysfunction, and mortality. These data should provide background information for future clinical trials of newer antiviral agents.
BACKGROUND: Antiviral-resistant or refractory cytomegalovirus (CMV) infection is challenging, and salvage therapies, foscarnet, and cidofovir, have significant toxicities. Several investigational anti-CMV agents are under development, but more information is needed on outcomes of current treatments to facilitate clinical trial design for new drugs. METHODS: Records of solid organ transplant (SOT) and hematopoietic cell transplant (HCT) recipients at a single center over a 10-year period were reviewed retrospectively to characterize those who had received foscarnet treatment for ganciclovir-resistant or refractory CMV infection. Data were collected on virologic responses, mortality, and nephrotoxicity. RESULTS: Of 39 patients (22 SOT, 17 HCT), 15 had documented ganciclovir resistance mutations and 11 (28%) of 39 had tissue-invasive CMV. Median duration of foscarnet was 32 days. Virologic failure occurred in 13 (33%) of 39 and relapses of viremia occurred in 31%. Mortality was 12 (31%) of 39 and was higher in HCT than SOT (P = 0.001), although ganciclovir resistance was more common in SOT (P = 0.003). Doses of ganciclovir or valganciclovir were low in 10 (26%) of 39 at some time before switching to foscarnet. Renal dysfunction occurred in 20 (51%) of 39 by end of treatment and in 7 (28%) of 25 after 6 months. CONCLUSIONS: Outcomes of existing treatment for ganciclovir-resistant or refractory CMV are suboptimal, in terms of virologic clearance, renal dysfunction, and mortality. These data should provide background information for future clinical trials of newer antiviral agents.
Authors: Frank M Mattes; Emma G Hainsworth; Anna-Maria Geretti; Gaia Nebbia; Grant Prentice; Michael Potter; Andrew K Burroughs; Paul Sweny; Aycan F Hassan-Walker; Sylvester Okwuadi; Caroline Sabin; Geraldine Amooty; Vanessa S Brown; Sarah C Grace; Vincent C Emery; Paul D Griffiths Journal: J Infect Dis Date: 2004-04-01 Impact factor: 5.226
Authors: D R Kaul; S Stoelben; E Cober; T Ojo; E Sandusky; P Lischka; H Zimmermann; H Rubsamen-Schaeff Journal: Am J Transplant Date: 2011-05 Impact factor: 8.086
Authors: Francisco M Marty; Drew J Winston; Scott D Rowley; Estil Vance; Genovefa A Papanicolaou; Kathleen M Mullane; Thomas M Brundage; Alice T Robertson; Susan Godkin; Hervé Momméja-Marin; Michael Boeckh Journal: N Engl J Med Date: 2013-09-26 Impact factor: 91.245
Authors: Cynthia E Fisher; Janine L Knudsen; Erika D Lease; Keith R Jerome; Robert M Rakita; Michael Boeckh; Ajit P Limaye Journal: Clin Infect Dis Date: 2017-07-01 Impact factor: 9.079
Authors: Arun Kapoor; Ayan K Ghosh; Michael Forman; Xin Hu; Wenjuan Ye; Noel Southall; Juan Marugan; Robert F Keyes; Brian C Smith; David J Meyers; Marc Ferrer; Ravit Arav-Boger Journal: J Med Chem Date: 2020-03-27 Impact factor: 7.446